Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Aug 8.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):183–190. doi: 10.1167/iovs.04-0330

Specific Targeting of Gene Expression to a Subset of Human Trabecular Meshwork Cells Using the Chitinase 3-Like 1 Promoter

Paloma B Liton 1, Xialin Liu 1, W Daniel Stamer 2, Pratap Challa 1, David L Epstein 1, Pedro Gonzalez 1
PMCID: PMC3152459  NIHMSID: NIHMS311634  PMID: 15623772

Abstract

Purpose

To compare the gene expression profile of trabecular meshwork (TM) and Schlemm’s canal (SC) primary cultures and to identify promoters for targeting gene expression to specific cells in the outflow pathway.

Methods

The differential gene expression profile of four human TM and three SC primary cultures was analyzed by gene microarrays (Affymetrix, Santa Clara, CA) and confirmed by quantitative real-time PCR. Based on the results, a recombinant adenovirus was constructed with the expression of the reporter gene LacZ driven by the 5′ promoter region of the chitinase 3-like 1 (Ch3L1) gene (AdCh3L1-LacZ). The expression of the Ch3L1 promoter was analyzed in human TM and SC cells and in human perfused anterior segments infected with AdCh3L1-LacZ.

Results

γ-Sarcoglycan, fibulin-2, and collagen XV were identified as the genes more highly expressed in SC than in TM cells. Ch3L1 showed the highest levels of differential expression in TM versus SC cells. Expression analysis of the Ch3L1 promoter demonstrated specific expression in a subset of the TM cells in cell culture and in perfused anterior segments.

Conclusions

Comparative analysis of gene expression between SC and TM primary cultures identified several genes with promoters potentially capable of targeting gene expression to specific cells within the outflow pathway. Results with the Ch3L1 promoter indicated that two different cell subtypes may be present in the TM. This study provides a new potential tool to investigate the role of these different cell types in both normal and pathophysiological function of the outflow pathway, with implications for possible future glaucoma gene therapy.

Glaucoma is a group of blinding disorders characterized by damage to the optic nerve. The most common form of the disease, primary open-angle glaucoma (POAG), is frequently associated with elevated intraocular pressure (IOP) that results from an abnormal resistance to the outflow of aqueous humor through the conventional outflow pathway.1,2 The conventional outflow pathway is the route by which most aqueous humor exits the anterior chamber of the eye, and it includes the trabecular meshwork (TM) and Schlemm’s canal (SC).3

The outflow pathway is a complex tissue composed of several different cell types that are morphologically and functionally different: (1) Schwalbe’s line (SL) cells are located in the anterior, nonfiltering portion of the TM and have been proposed to be the progenitor cells of the TM; (2) TM cells cover the surface of the connective tissue beams in both the uveal and corneoscleral filtering meshwork and appear to be involved in phagocytosis and tissue remodeling; (3) juxtacanalicular tissue (JCT) cells are randomly distributed within the extracellular matrix of the juxtacanalicular meshwork; and (4) the cells of the inner wall endothelium of SC constitute the only continuous cell layer in the outflow pathway.4,5 The specific functional differences of these cells and their role in the physiology of the aqueous humor process are not clear. Although the locus of both normal outflow resistance and the abnormal resistance in POAG is believed to be at the level of the JCT and/or the inner wall of SC,6–8 there is uncertainty as to the exact location. Although one school of thought postulates that the extracellular material within the JCT is responsible for normal resistance, the other school of thought emphasizes the role of the cells of the inner wall of SC as the major locus of the outflow resistance.7,9–13

A potential strategy for understanding these questions, which also has therapeutic implications, is directed gene delivery to specific cell types within the outflow pathway. We have recently demonstrated the feasibility of targeting gene expression to the outflow pathway with replication-deficient adenoviruses containing tissue-specific promoters that were identified from gene expression profile analyses of the TM.14 Analyses of the published TM libraries have provided important information about the genes preferentially expressed in the outflow pathway compared with other tissues18–20; however, the specimens used in these analyses also include cells from the inner wall of SC. Therefore, the identification of genes differentially expressed in the TM and SC is the next logical step in planning further experiments targeting specific cell types.

One experimental approach for the identification of such differential markers is the comparison of gene expression profiles. However, because of the small size and complexity of the outflow pathway, it is impractical to dissect only the SC endothelia, making the construction of a direct SC cDNA library almost impossible. As an alternative approach, we present a comparative gene expression profile analyses between human primary cultured TM and SC cells. We identified genes with promoters potentially capable of targeting gene expression in specific cells in the outflow pathway. The expression of one of these promoters was tested in both TM cells and SC cells, and also in human perfused anterior segments.

Materials and Methods

Cell Cultures

Primary cultures of human TM and SC cells were prepared from donor eyes as previously described15,16 and maintained at 37°C in 5% CO2 in low-glucose Dulbecco’s modified Eagle’s medium (DMEM) with L-glutamine and 110 mg/L sodium pyruvate, supplemented with 10% fetal bovine serum (FBS), 100 μM nonessential amino acids, 100 U/mL penicillin, 100 μg/mL streptomycin sulfate, and 0.25 μg/mL amphotericin B. All the reagents were obtained from Invitrogen Corp. (Carlsbad, CA). The protocols involving the use of human tissue were consistent with the tenets of the Declaration of Helsinki.

RNA Extraction

Human TM and SC primary cultures at passage three were grown to confluence. After the culture medium was removed, cells were immediately immersed in preservative (RNA later; Ambion Inc., Austin, TX) to maintain the integrity of the RNA. Total RNA was then isolated (RNeasy kit; Qiagen Inc., Valencia, CA), according to the manufacturer’s protocol and treated with DNase. RNA yields were determined with a fluorescent dye (RiboGreen; Molecular Probes, Inc., Eugene, OR).

Gene Microarray Analysis

Total RNA (10 μg) from four different human TM cultures and three different SC cultures was hybridized independently to U95Av2 human arrays (Affymetrix, Santa Clara, CA) at the Duke University Microarray Facility, according to the manufacturer’s protocol.

The signal values for each specific gene were normalized using the mean signal value from all probe sets in the array. The difference in expression (x-fold) between human TM (HTM) and SC cells for each gene were calculated by comparing the mean normalized signal values of the gene from the four arrays hybridized with HTM cell probes and those from the three arrays hybridized with SC cell probes.

Quantitative Real-Time PCR

First-strand cDNA was synthesized from total RNA (1 μg) by reverse transcription using oligodT primer and reverse transcriptase (Superscript II; Invitrogen) according to the manufacturer’s instructions. Real-time PCR reactions were performed in a 20-μL mixture containing 1 μL of the cDNA preparation, 1× PCR mix (iQ SYBR Green Supermix; Bio-Rad, Hercules, CA), and 500 nm of each primer, in a thermocycler (iCycler iQ system; Bio-Rad) using the following PCR parameters: 95°C for 5 minutes followed by 50 cycles at 95°C for 15 seconds, 65°C for 15 seconds, and 72°C for 15 seconds. The fluorescence threshold (Ct) was calculated with the system software. The absence of nonspecific products was confirmed by both the analysis of the melting-point agarose curves and by electrophoresis in 3% gels. β-Actin served as an internal standard of mRNA expression. The sequences of the primers used for the amplifications are shown in Table 1.

Table 1.

Primer Sequences Used for the Real-Time PCR Analysis

Gene Primers
Ch3L1 Forward 5′-TCCCCTATGCCACCAAGGGCAAC-3′
Reverse 5′-CCATACCATGGCGCCTGCCAGC-3′
Matrix Gla protein Forward 5′-CCAAGAGAGGATCCGAGAACG-3′
Reverse 5′-ATCCATAAACCATGGCGTAGC-3′
Angiopoietin-like factor Forward 5′-AACGAACACATCCACCGGCTCTC-3′
Reverse 5′-GTGGCTATACTCAGCGTAGCGCAG-3′
γ-Sarcoglycan Forward 5′-CGCTGGGAAAATTGAGGCGCTTTC-3′
Reverse 5′-CCACGTCCCCTGCACCAGCTTGG-3′
Collagen XV Forward 5′-CCTGCTCTGCATTTGGCTGCTCTG-3′
Reverse 5′-AACAGTCCTGCAGCTCTGGCCTG-3′
Fibulin-2 Forward 5′-TCCACCCTAGCTTCCGCTGCCTG-3′
Reverse 5′-AAGTCATGGCACGTGGTGCGCTCG-3′
β-Actin Forward 5′-CCTCGCCTTTGCCGATCCG-3′
Reverse 5′-GCCGGAGCCGTTGTCGACG-3′
Open in a new tab

Generation of the Recombinant Adenovirus

For the generation of the replication-deficient recombinant adenovirus AdCh3L1-LacZ, a 1059-bp DNA fragment containing the 5′ region of the Ch3L1 gene was amplified by PCR from 100 ng of human genomic DNA (BD-Clontech, Palo Alto, CA) using the specific primers: Chi3L1-forward 5′-CTCGAGTTAAGCCTGCAAAGAATGGAGT-3′, and Chi3L1-reverse 5′-CAAGCTTGCCCACGGCTCCTGGTGCCAGCT-3′, which contain the restriction sites for XhoI and HindIII, respectively. The PCR reaction was performed at 94°C for 15 seconds followed by 35 cycles of 68°C for 15 seconds and 72°C for 60 seconds (Advantage-HF PCR kit; BD-Clontech). The PCR product was purified and cloned into TOPO TA (Invitrogen) for sequencing. The product with the correct sequence was released by digestion with XhoI and HindIII (New England BioLabs, Beverly, MA) and introduced into a modified pShuttle (Stratagene, La Jolla, CA) containing the LacZ gene and the SV40 polyadenylation signal (pShuttle-LacZ). This pShuttle-LacZ with the Ch3L1 promoter was used to generate the replication-deficient recombinant adenovirus (AdCh3L1-LacZ) using a commercial system (Ad-Easy; Stratagene). The generation of the AdMGP-LacZ containing a matrix Gla protein (MGP) promoter fragment (550 to +27) has been described.14

Analysis of Ch3L1 Promoter Expression in Primary Cultures of HTM and SC Cells

Confluent cultures of human TM or SC cells at passage three were infected with 100 pfu/cell of either the AdCh3L1-LacZ or the AdMGP-LacZ recombinant adenovirus. Two days after infection, β-galactosidase expression was analyzed.

Analysis of β-Galactosidase Activity

Cells were fixed in 1% paraformaldehyde, 0.2% glutaraldehyde, 0.02% NP40, and 0.01% sodium deoxycholate in PBS. After two washes with PBS, β-galactosidase activity was detected by overnight incubation at 37°C in 1 mg/mL 5-bromo-4-chloro-3 β-D-galactoside, 5 mM K3Fe(CN), 5 mM K4Fe(CN)6-3H2O, and 2 mM Mg2Cl in PBS. For the detection of β-galactosidase in organ cultures, anterior segments were fixed by perfusion at 15 mm Hg, removed from the perfusion system, and stained overnight in the staining solution. After color development, the segments were postfixed in 10% neutral buffered formalin, dehydrated in an ethanol and xylene series, and embedded in paraffin. Sections (5–6 μm) were then counterstained (Hematoxylin QS; Vector Laboratories, Burlingame, CA).

Perfusion of Human Eye Anterior Segments

Organ cultures of human anterior segments were performed using the method described by Johnson and Tschumper.17 Briefly, human cadaveric eyes (ages, 33–74 years) <48 hours after death were bisected at the equator, and the lens, iris, and vitreous were removed. The anterior segments were then clamped to a modified Petri dish and perfused by a microinfusion pump at a constant flow of 3 μL per minute with serum-free, high-glucose DMEM supplemented with 110 mg/L sodium pyruvate, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 170 μg/mL gentamicin, and 250 μg/mL amphotericin B. Perfused anterior segments were incubated at 37°C in 5% CO2. Intraocular pressures were continuously monitored with a pressure transducer connected to the dish’s second cannula and recorded with an automated computerized system. Only anterior segments with a stable outflow facility between 0.09 and 0.40 μL/min per mm Hg that remained unchanged after viral infection were used.

Analysis of Ch3L1 Promoter Expression in Perfused Organ Cultures

Anterior segments of human eyes were cultured as described earlier. After 48 hours of perfusion, the pumps were stopped, and the pressure dropped to <5 mm Hg. The segments were inoculated with 107 pfu of AdCh3L1-LacZ in 100 μL of perfusion medium at 3 μL/min. Once the total volume was inoculated, the normal perfusion regimen was resumed. β-Galactosidase activity was examined at 2 days after infection. Six eyes from different donors were analyzed for the expression of the Ch3L1 promoter.

Results

Genes Differentially Expressed in TM and SC Cells

The gene expression profiles of four primary TM cultures and three primary SC cultures were analyzed in parallel by oligo-nucleotide gene microarray (Affymetrix). Data resulting from these arrays are available on request. The genes more significantly expressed in SC than in the TM are shown in Table 2, and the genes more significantly expressed in the TM than in the SC are shown in Table 3. To confirm the experimental results of the arrays, we performed quantitative real-time PCR on Ch3L1, MGP, and CDT6, as representative of TM genes, and on γ-sarcoglycan (SGCG), collagen XV (COL15), and fibulin-2 (FBLN2), as representative of SC cells. The differential expression (x-fold) was calculated from the Ct values (Fig. 1).

Table 2.

Genes More Differentially Expressed in SC Cells than in TM Cells

Gene Name Unigene* SC TM x-Fold
γ-Sarcoglycan Hs.37167 974 ± 1202 12 ± 3 82
Collagen, type XV, alpha 1 Hs.409034 1024 ± 723 17 ± 12 59
Fibulin 2 Hs.198862 4645 ± 601 153 ± 82 30
Cysteine-rich protein 1 (intestinal) Hs.423190 1858 ± 890 90 ± 48 21
Wingless-type MMTV integration site family member 2 Hs.89791 1078 ± 823 61 ± 21 18
Phosphoserine phosphatase-like Hs.369508 338 ± 264 26 ± 19 13
Meningioma 1 Hs.268515 1565 ± 461 120 ± 128 13
Similar to rat myomegalin Hs.390449 235 ± 106 19 ± 20 12
Dermatopontin Hs.80552 295 ± 168 24 ± 16 12
Cysteine knot superfamily 1 Hs.40098 1496 ± 1352 150 ± 93 10
Calcium channel, voltage-dependent, beta 4 subunit Hs.284800 316 ± 25 35 ± 21 9
Microfibril-associated glycoprotein-2 Hs.300946 1357 ± 762 156 ± 82 9
Neuronal PAS domain protein 1 Hs.79564 451 ± 389 55 ± 27 8
Chemokine (C-X-C motif) ligand 12 Hs.436042 5481 ± 3195 677 ± 485 8
Insulin-like growth factor 2 Hs.349109 347 ± 246 43 ± 47 8
Phospholipase A2, group IIA Hs.76422 447 ± 484 56 ± 37 8
Neurotrophin 3 Hs.99171 217 ± 57 27 ± 16 8
WNT1 inducible signaling pathway protein 2 Hs.194679 2436 ± 737 372 ± 35 7
D component of complement Hs.155597 1221 ± 825 202 ± 30 6
Keratin 7 Hs.23881 1542 ± 1080 268 ± 177 6
Open in a new tab
*

http://www.ncbi.nlm.nih.gov/UniGene; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD.

Table 3.

Genes More Differentially Expressed in TM Cells than in SC Cells

Gene Name UniGene* TM SC x-Fold
Chitinase 3-like 1 Hs.382202 23881 ± 12927 147 ± 134 162
Myocilin Hs.78454 2033 ± 1545 18 ± 17 115
Vascular cell adhesion molecule 1† Hs.109225 739 ± 481 10 ± 1 77
Interleukin 11 Hs.1721 427 ± 733 6 ± 5 74
Apolipoprotein E Hs.169401 2759 ± 2424 50 ± 23 55
Cyclooxygenase-2 (hCox-2) Hs.196384 1291 ± 1201 26 ± 14 51
Stanniocalcin 1 Hs.25590 3516 ± 5286 86 ± 71 41
Retinoic acid receptor responder 1 Hs.82547 3564 ± 2764 99 ± 92 36
Matrix Gla protein Hs.365706 2425 ± 3187 76 ± 61 32
Regulator of G-protein signalling 5 Hs.24950 924 ± 832 39 ± 9 24
Angiopoietin-like factor Hs.146559 223 ± 271 10 ± 11 23
Prostaglandin E receptor 2 Hs.2090 978 ± 569 46 ± 21 21
Vascular cell adhesion molecule 1† Hs.109225 603 ± 417 30 ± 19 20
Tumor necrosis factor (ligand) superfamily, member 10 Hs.387871 874 ± 793 46 ± 18 19
EphB2 Hs.125124 652 ± 210 36 ± 19 18
Guanylate cyclase 1, soluble, alpha 3 Hs.433488 515 ± 642 35 ± 32 15
Aldo-keto reductase family 1, member B10 Hs.116724 2772 ± 839 199 ± 78 14
Fibroblast growth factor receptor 2 Hs.404081 527 ± 303 38 ± 26 14
Neuronal Shc adaptor homolog Hs.30965 392 ± 57 31 ± 18 13
Growth differentiation factor 5 Hs.1573 527 ± 423 44 ± 23 12
Open in a new tab
*

See Table 2.

†

Results correspond to two different probe sets for vascular cell adhesion molecule 1 present in the array.

Figure 1.

Figure 1

Open in a new tab

Confirmation of the differential expression between human TM and SC cultured cells by real-time PCR. Expression differences (x-fold) based on the fluorescence threshold values (Ct) calculated using the thermocycler software are presented for three genes with promoters potentially useful for targeting gene expression to TM but not SC cells: Ch3L1, MGP, and CDT6; and three genes with promoters potentially useful for targeting gene expression to SC but not TM cells: COLXV, FBLN2, and SGCG.

Analysis of the Gene Expression Profile of Primary HTM and SC Cultures

The gene expression profiles of primary TM and SC cell cultures were compared with the previously published cDNA libraries from TM tissue and infant TM cell culture.18–20 In Table 4, the genes with a signal expression higher than 20,000 in either the TM or SC are compared with the genes more highly represented in the libraries. To simplify the data, we excluded the generally highly expressed ribosomal proteins from the analysis. EF-1α was the only common gene found to be among the most highly expressed genes in the four studies. Table 5 shows genes reported to be highly expressed in human TM tissue, either in revived or nonrevived organs, whose expression was found to be significantly lost in the TM and SC cultured cells.

Table 4.

Summary of the Genes Highly Expressed in Human TM and SC Cells

Gene Name UniGene ID* Signal Values ± SD
Gonzalez et al.18 Tomarev et al.19 Wirtz et al.20
TM SC
Ferritin, light polypeptide Hs.433670 34375 ± 11034 36156 ± 13589 † †
Elongation factor EF-1α Hs.439552 29910 ± 9533 34764 ± 14285 † † †
Tissue inhibitor of metalloproteinases 1 (TIMP1) Hs.446641 33826 ± 11139 30003 ± 11521 † †
Actin, β Hs.426930 28991 ± 10727 32043 ± 20571
Glyceraldehyde-3-phosphate dehydrogenase Hs.169476 31614 ± 10521 31739 ± 16310 † †
Vimentin Hs.439800 26015 ± 6654 31593 ± 14506 †
Ferritin, heavy polypeptide 1 Hs.418650 25700 ± 7010 31519 ± 10687 †
Thymosin, β4 Hs.79968 24290 ± 7485 28860 ± 10761 † †
Interferon induced transmembrane protein 1 (9–27) Hs.374690 28277 ± 7902 25567 ± 7671
Insulin-like growth factor binding protein 4 Hs.1916 27961 ± 8632 18958 ± 6426
Clusterin Hs.436657 27838 ± 11408 13288 ± 5795
Interferon-induced transmembrane protein 3 (1-8U) Hs.374690 26719 ± 8925 24778 ± 7492
Guanine nucleotide binding protein (G protein) Hs.5662 22201 ± 7451 26601 ± 10629
Laminin receptor 1 Hs.356261 21332 ± 6765 26547 ± 10797
Lectin, galactoside-binding, soluble, 1 Hs.407909 21658 ± 4720 25810 ± 13272
Annexin A2 Hs.437110 21806 ± 3573 25309 ± 8783
β-2-microglobulin Hs.48916 25199 ± 9487 24499 ± 4905 †
Actin, γ1 Hs.14376 21377 ± 7608 24787 ± 12811
Chitinase 3-like 1 Hs.382202 23881 ± 12927 147 ± 134 †
Ubiquitin C Hs.183704 20307 ± 3715 22451 ± 8342
Fibronectin 1 Hs.418138 18032 ± 10516 20822 ± 9363 †
Nonmuscle/smooth muscle alkali myosin light chain Hs.77385 18285 ± 3683 20624 ± 8476
Open in a new tab
*

See Table 2.

†

Transcripts highly represented in libraries from perfused TM,18 postmortem TM,19 and infant primary TM culture.20

Table 5.

Summary of the Genes That Appear to be Downregulated in TM and SC Primary Cultures Compared with the TM Tissue

Gene Name UniGene ID* HTM
SC
Gonzalez et al.18
 Tomarev et al. 19
Rank SV ± SD Rank SV ± SD Rank n Rank n
SPARC-like 1 Hs.75445 8375 64 ± 59 10528 25 ± 12 23 10
Matrix metalloproteinase 3 Hs.375129 7729 86 ± 100 8884 54 ± 22 17 4
Purkinje cell protein 4 Hs.80296 6411 151 ± 88 9567 40 ± 14 9 14
Small inducible cytokine Hs.105656 5739 198 ± 31 4353 334 ± 70 13 4
Angiopoietin like factor Hs.146559 5395 223 ± 271 11929 10 ± 10 15 13
v-Fos Hs.25647 4475 314 ± 155 5989 182 ± 20 36 8
Apoliprotein D Hs.75736 3809 408 ± 55 1438 1308 ± 1567 8 6 8 15
Decorin Hs.156316 2066 696 ± 273 2542 704 ± 233 21 10
Regulator of G-protein signal Hs.24950 2896 924 ± 832 7539 39 ± 9 14 4 14 13
Myocilin Hs.78454 982 2033 ± 1546 11095 18 ± 17 3 28
β-Tubulin Hs.300701 979 2041 ± 908 581 3427 ± 1147 16 4
Matrix Gla Protein Hs.365706 841 2425 ± 3187 8107 76 ± 60 4 9 5 22
CREBBP/EP300 inhibitory protein Hs.381137 751 2724 ± 283 893 2176 ± 781 31 9
Prothymosin α Hs.264317 633 3145 ± 1002 694 2828 ± 562 29 9
Phosphatase type 2B Hs.432840 483 4116 ± 1086 349 5651 ± 4523 45 7
Triosephosphate isomerase Hs.83848 440 4462 ± 1922 1072 1788 ± 425 12 5
Cytochrome c oxidase VIIc Hs.430075 240 5287 ± 1003 456 4412 ± 751 40 7
Tropomyosin α Hs.133892 349 5501 ± 2324 242 7739 ± 6489 6 18
α-Tubulin Hs.446608 303 6212 ± 2688 309 6465 ± 2032 15 4
Tumor protein TPT1 Hs.374596 257 6880 ± 1156 180 9806 ± 3325 4 27
Nascent-polypeptide-associated Hs.32916 219 7870 ± 1744 189 9632 ± 2444 11 14
NADH dehydrogenase 1 α Hs.83916 204 8322 ± 1552 269 7216 ± 754 32 9
Lysosomal-associated protein Hs.111894 161 8608 ± 1569 171 7964 ± 432 38 8
Heat Shock Protein 90 Hs.446579 183 9152 ± 2154 276 7003 ± 1977 9 5
CTGF Hs.410037 150 10960 ± 5109 250 7546 ± 1885 43 7
Lactate dehydrogenase Hs.2795 138 11284 ± 1411 178 9979 ± 3746 7 7
Actin α2 Hs.208641 114 12526 ± 7959 346 5671 ± 2907 19 11
Open in a new tab

SV, signal value; n, number of individual clones.

*

See Table 2.

Expression of the Ch3L1 Promoter in Primary TM and SC Cultures

To test the specificity of Ch3L1, we constructed a replication-deficient recombinant adenovirus in which the expression of the LacZ reporter gene was driven by the 5′ promoter region of the Ch3L1 gene (AdCh3L1-LacZ). Human TM and SC cells were infected with the recombinant adenovirus AdCh3L1-LacZ, and β-galactosidase activity was investigated. Consistent with the arrays, no β-galactosidase staining was detected in SC cells (Fig. 2A). Despite the high multiplicity of infection (MOI = 100 pfu/cell), only approximately 50% of cells in the TM culture stained positively for β-galactosidase (Fig. 2B). All the TM cells, however, showed strong β-galactosidase activity when infected with AdMGP-LacZ, a reported positive marker for TM cells, using the same MOI of 100 pfu/cell (Fig. 2C).

Figure 2.

Figure 2

Open in a new tab

Expression analysis of the Ch3L1 promoter. Cells from primary cultures of SC and TM cells and from perfused human anterior segments were infected with the AdCh3L1-LacZ recombinant adenovirus expressing the reporter gene LacZ under the control of a 1059-bp fragment of the Ch3L1 promoter, and analyzed for β-galactosidase expression 48 hours after infection. (A) Primary cultures of human SC cells did not show any detectable expression of the Ch3L1 promoter. (B) Primary cultures of HTM cells showed a mixture of Ch3L1 positive and negative cells indicative of the presence of at least two subpopulations with distinct patterns of gene expression. (C) Control cultures infected with the AdMGP-LacZ virus demonstrated that virtually all the cells in the culture expressed this TM marker. (D) Perfused anterior segments from human eyes showed preferential expression in the TM and in blood vessels of the sclera. (E) Low-magnification view of paraffin sections showed Ch3L1 expression preferentially located in the anterior and posterior regions of the TM. (F) Higher magnification views of paraffin sections also demonstrated the presence of a mixture of positive and negative Ch3L1 cells in the tissue. Similar results including lack of detectable expression in SC cells and heterogeneous staining of TM cells were obtained in both, primary cultures from three different cell lines, and in organ culture from six perfused anterior segments.

Expression of the Ch3L1 Promoter in the Outflow Pathway

Injection of anterior segments with AdCh3L1-LacZ shows β-galactosidase expression restricted to the TM region (Fig. 2D). In the six pairs of eyes analyzed, Ch3L1 promoter activity was detectable in the most anterior and posterior regions of the TM next to the sclera spur and SL, but not in the middle area (Fig. 2E). Most of the staining was found to be in the trabecular cells, although some β-galactosidase activity was observed in the juxtacanalicular cells of some of the eyes (Fig. 2F).

Discussion

Given the important role of the aqueous humor outflow pathway in modulating IOP, there has been increasing interest in the development of methods for gene transfer to the cells of this tissue for both therapeutic and experimental purposes.21–28 We have recently demonstrated the feasibility of specific gene delivery to the cells of the outflow pathway using an adenoviral vector containing a tissue specific promoter.14 In the present study, we have focused on the identification of differential markers by comparing the gene expression profile of human TM and SC cells. Our objective was to identify promoters capable of targeting gene expression in specific cell types within the outflow pathway.

The data from the comparative analysis show a surprisingly low number of potential specific markers for SC cells, perhaps partially because of the presence of cells from the inner wall of the SC in the TM primary cultures, which thus may have resulted in the expression of SC-specific genes in the TM cultures. The genes most differentially expressed in SC cells compared to TM cells were SGCG, COL15, and FBLN2. Given the lack of information about the function of SGCG, a glycoprotein mainly expressed in muscle cells, it is difficult to speculate about its possible role in SC function.29–31 In addition, this gene shows a relatively low signal value and high variability among the samples.

Potentially more relevant to the specific functions of SC may be the expression of COL15 and FBLN2. COL15 is present in the basement membrane of many mesenchymally derived cells, including endothelial cells.32–34 The proteolytically processed C-terminal fragment of COL15 functions as an endostatin, an inhibitor of endothelial cell migration and angiogenesis.35–38 This fragment also appears to interact with FBLN2,39 an extracellular matrix protein abundant in vessel walls and basement membranes,40,41 whose expression has been reported to be modulated by dexamethasone,42 an agent known to cause temporary glaucoma. Although the specific role of FBLN2 and the biological consequences of its interaction with the endostatin domain of COL15 are still unknown, the expression of these two genes in SC cells may support the vascular origin theory of SC.43,44

The comparative analysis of the gene expression profile of TM and SC cells revealed Ch3L1 as a potential differential marker for TM cells, because it was one of the more abundant transcripts in TM cells and was practically absent in SC cultures. Ch3L1, also called human cartilage glycoprotein-39 (HC-gp39 or YKL-40), is a mammalian glycoprotein member of family 18 glycosyl hydrolases.45,46 High production of Ch3L1 is detected in the cartilage of rheumatoid arthritis patients,46–50 in various inflammatory disorders,51–53 in the liver of patients with alcoholic cirrhosis,54,55 in several types of cancer,56–60 and in macrophages in atherosclerotic plaques.61–63 Although the biological function of this protein is still unknown, it is thought to be involved in tissue remodeling and inflammation, acting as a growth factor for connective tissue cells and as a potent migration factor for endothelial cells.64–66 Therefore, Ch3L1 could play a role in both the normal physiology of the TM and the abnormalities that occur in glaucoma.

The gene expression profiles deduced from our gene array analysis of both TM and SC primary cultures show relatively low consistency with previous studies, which notably also exhibited important discrepancies among themselves.18–20 These inconsistencies may result from differences in both the methodology and the specific models used for the analysis. While all the other studies were performed using the cDNA library technology, the study presented herein was performed by gene microarrays (Affymetrix). To date, there is still not enough information regarding how these two platforms compare with each other; however, discrepancies have been observed, for instance, when comparing the most highly expressed genes in pancreatic adenocarcinoma, by different profiling technologies.67

Another factor is that none of these prior studies were based on the same model. Since our study used cultured TM and SC cells, the study of Gonzalez et al.18 was based on one perfused human eye; Tomarev et al.19 analyzed the expression profile of a pool of native donor eyes; and Wirzt et al.20 used primary cultures of TM from infant donors. Differences in gene expression among cultured cells, organ culture, and donor tissue should be anticipated and have, in fact, been reported.68 These differences may be due to several factors, including changes in the tissue microenvironment, differences between culture medium and aqueous humor, and the ages of the donors. Given this level of discrepancy, further analyses with both intact and individual tissues are necessary to obtain a more accurate gene expression profile for outflow pathway cells.

Based on our results from these arrays, we selected Ch3L1, the gene with the highest level of differential expression between TM and SC cells, as a potential promoter for specific gene expression delivery to the TM cells. At the time the experiments were performed, the promoter of Ch3L1 had not been characterized; however, a recently published work has confirmed that the 5′ fragment that we amplified to make the construct contains the fully functional Ch3L1 promoter.69

The lack of expression of the Ch3L1 promoter in SC cells from both primary cultured cells and organ culture was clearly consistent with the data from the arrays. However, a surprising result that contrasted with previously reported data on the expression of the MGP promoter in the outflow pathway14 was the heterogeneity in the expression of the Ch3L1 promoter in TM cells. This may suggest the existence of at least two sub-populations of cells in human TM primary cultures. The pattern of β-galactosidase activity in histologic sections from eyes perfused with the AdCh3L1-LacZ showed that these two subtypes of cells do not correspond simply to trabecular or juxtacanalicular cells, because, in the six pairs of eyes analyzed, the β-galactosidase staining was detectable in the most anterior and posterior regions of the TM next to the sclera spur and SL, but not in the middle area, regardless of cell type.

As mentioned earlier, Ch3L1 protein is commonly produced in pathologic conditions involving inflammation and tissue remodeling. The distribution of positive-stained cells in the outflow pathway could reflect the areas that are subject to strong mechanical stress and, therefore, are involved in induced changes in extracellular matrix composition.70

We hypothesize that changes in the expression of Ch3L1 protein could be involved in the mechanism of abnormal resistance found in many forms of open-angle glaucoma. Ch3L1 has been reported to be upregulated after treatment of human TM cells with dexamethasone,71 and also in the retina in a monkey glaucoma model.72 The observation that Ch3L1 was not detected among the clones analyzed in the cDNA library of cultured TM cells from infant donors20 is consistent with the suggested correlation between Ch3L1 expression and aging,73 and we hypothesize that many glaucomas involve accelerated cellular processes of aging.

In conclusion, the comparative analyses of gene expression profiles of SC and the TM cells provide new insight on the differences between these two cell types that could lead to a new understanding of their respective physiologic roles. Our study identified several genes with promoters potentially useful for targeting gene expression in specific cell types within the outflow pathway. In addition, the expression analysis of a promoter fragment from one such gene, Ch3L1, indicates that the TM may have different cell subtypes distinguishable at the molecular level. This would suggest that the cellular composition of this tissue may be even more complex than initially thought.

Acknowledgments

Supported in part by The Research to Prevent Blindness Foundation, The Glaucoma Foundation, and National Eye Institute Grants P30 EY05722 and EY01894-25.

Footnotes

Disclosure: P.B. Liton, None; X. Liu, None; W.D. Stamer, None; P. Challa, None; D.L. Epstein, None; P. Gonzalez, None

References

  • 1.Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989;107:186–188. doi: 10.1016/0002-9394(89)90221-3. [DOI] [PubMed] [Google Scholar]
  • 2.Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097–1106. doi: 10.1056/NEJM199304153281507. [DOI] [PubMed] [Google Scholar]
  • 3.Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res. 1971;12:275–281. doi: 10.1016/0014-4835(71)90149-7. [DOI] [PubMed] [Google Scholar]
  • 4.Tripathi R, Tripathi B. Functional anatomy of the chamber angle. In: Jacobiec F, editor. Ocular Anatomy, Embryology and Teratology. Philadelphia: Harper Row; 1982. pp. 197–248. [Google Scholar]
  • 5.Lütjen-Drecoll E. Functional morphology of the trabecular mesh-work in primate eyes. Prog Retin Eye Res. 1999;18:91–119. doi: 10.1016/s1350-9462(98)00011-1. [DOI] [PubMed] [Google Scholar]
  • 6.Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783–801. doi: 10.1001/archopht.1963.00960040789022. [DOI] [PubMed] [Google Scholar]
  • 7.Maepea O, Bill A. Pressures in the juxtacanalicular tissue and Schlemm’s canal in monkeys. Exp Eye Res. 1992;54:879–883. doi: 10.1016/0014-4835(92)90151-h. [DOI] [PubMed] [Google Scholar]
  • 8.Brubaker RF. The effect of intraocular pressure on conventional outflow resistance in the enucleated human eye. Invest Ophthalmol. 1975;14:286–292. [PubMed] [Google Scholar]
  • 9.Bill A, Svedbergh B. Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm: an attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol (Copenh) 1972;50:295–320. doi: 10.1111/j.1755-3768.1972.tb05954.x. [DOI] [PubMed] [Google Scholar]
  • 10.Johnson M, Shapiro A, Ethier CR, Kamm RD. Modulation of out-flow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci. 1992;33:1670–1675. [PubMed] [Google Scholar]
  • 11.Johnstone MA. Pressure-dependent changes in nuclei and the process origins of the endothelial cells lining Schlemm’s canal. Invest Ophthalmol Vis Sci. 1979;18:44–51. [PubMed] [Google Scholar]
  • 12.Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649–2658. [PubMed] [Google Scholar]
  • 13.Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM. Calculations of flow resistance in the juxtacanalicular mesh-work. Invest Ophthalmol Vis Sci. 1986;27:1741–1750. [PubMed] [Google Scholar]
  • 14.Gonzalez P, Caballero M, Liton PB, Stamer WD, Epstein DL. Expression analysis of the matrix GLA protein (MGP) and VE-cadherin (VE-cad) gene promoters in the outflow pathway. Invest Ophthalmol Vis Sci. 2004;45:1389–1395. doi: 10.1167/iovs.03-0537. [DOI] [PubMed] [Google Scholar]
  • 15.Stamer WD, Roberts BC, Howell DN, Epstein DL. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995;14:611–617. doi: 10.3109/02713689508998409. [DOI] [PubMed] [Google Scholar]
  • 16.Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation, culture, and characterization of endothelial cells from Schlemm’s canal. Invest Ophthalmol Vis Sci. 1998;39:1804–1812. [PubMed] [Google Scholar]
  • 17.Johnson DH, Tschumper RC. Human trabecular meshwork organ culture: a new method. Invest Ophthalmol Vis Sci. 1987;28:945–953. [PubMed] [Google Scholar]
  • 18.Gonzalez P, Epstein DL, Borras T. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest Ophthalmol Vis Sci. 2000;41:3678–3693. [PubMed] [Google Scholar]
  • 19.Tomarev SI, Wistow G, Raymond V, Dubois S, Malyukova I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest Ophthalmol Vis Sci. 2003;44:2588–2596. doi: 10.1167/iovs.02-1099. [DOI] [PubMed] [Google Scholar]
  • 20.Wirtz MK, Samples JR, Xu H, Severson T, Acott TS. Expression profile and genome location of cDNA clones from an infant human trabecular meshwork cell library. Invest Ophthalmol Vis Sci. 2002;43:3698–3704. [PubMed] [Google Scholar]
  • 21.Borras T, Matsumoto Y, Epstein DL, Johnson DH. Gene transfer to the human trabecular meshwork by anterior segment perfusion. Invest Ophthalmol Vis Sci. 1998;39:1503–1507. [PubMed] [Google Scholar]
  • 22.Borras T, Rowlette LL, Erzurum SC, Epstein DL. Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow: relevance for potential gene therapy of glaucoma. Gene Ther. 1999;6:515–524. doi: 10.1038/sj.gt.3300860. [DOI] [PubMed] [Google Scholar]
  • 23.Budenz DL, Bennett J, Alonso L, Maguire A. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1995;36:2211–2215. [PubMed] [Google Scholar]
  • 24.Hangai M, Tanihara H, Honda Y, Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci. 1998;39:509–516. [PubMed] [Google Scholar]
  • 25.Liu X, Brandt CR, Gabelt BT, et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res. 1999;69:385–395. doi: 10.1006/exer.1999.0711. [DOI] [PubMed] [Google Scholar]
  • 26.Loewen N, Fautsch MP, Peretz M, et al. Genetic modification of human trabecular meshwork with lentiviral vectors. Hum Gene Ther. 2001;12:2109–2119. doi: 10.1089/10430340152677449. [DOI] [PubMed] [Google Scholar]
  • 27.Loewen N, Bahler C, Teo WL, et al. Preservation of aqueous outflow facility after second-generation FIV vector-mediated expression of marker genes in anterior segments of human eyes. Invest Ophthalmol Vis Sci. 2002;43:3686–3690. [PubMed] [Google Scholar]
  • 28.Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci. 2001;42:2856–2860. [PubMed] [Google Scholar]
  • 29.Ueda H, Ueda K, Baba T, Ohno S. Delta- and gamma-Sarcoglycan localization in the sarcoplasmic reticulum of skeletal muscle. J Histochem Cytochem. 2001;49:529–538. doi: 10.1177/002215540104900413. [DOI] [PubMed] [Google Scholar]
  • 30.Barresi R, Moore SA, Stolle CA, Mendell JR, Campbell KP. Expression of gamma-sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycan-sarcospan complex. J Biol Chem. 2000;275:38554–38560. doi: 10.1074/jbc.M007799200. [DOI] [PubMed] [Google Scholar]
  • 31.Wakayama Y, Inoue M, Kojima H, et al. Ultrastructural localization of alpha-, beta- and gamma-sarcoglycan and their mutual relation, and their relation to dystrophin, beta-dystroglycan and beta-spectrin in normal skeletal myofiber. Acta Neuropathol (Berl) 1999;97:288–296. doi: 10.1007/s004010050987. [DOI] [PubMed] [Google Scholar]
  • 32.Kivirikko S, Saarela J, Myers JC, Autio-Harmainen H, Pihlajaniemi T. Distribution of type XV collagen transcripts in human tissue and their production by muscle cells and fibroblasts. Am J Pathol. 1995;147:1500–1509. [PMC free article] [PubMed] [Google Scholar]
  • 33.Myers JC, Dion AS, Abraham V, Amenta PS. Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res. 1996;286:493–505. doi: 10.1007/s004410050719. [DOI] [PubMed] [Google Scholar]
  • 34.Hagg PM, Hagg PO, Peltonen S, Autio-Harmainen H, Pihlajaniemi T. Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol. 1997;150:2075–2086. [PMC free article] [PubMed] [Google Scholar]
  • 35.Cho H, Kim WJ, Lee YM, et al. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Oncol Rep. 2004;11:191–195. [PubMed] [Google Scholar]
  • 36.John H, Preissner KT, Forssmann WG, Standker L. Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. Biochemistry. 1999;38:10217–10224. doi: 10.1021/bi990787+. [DOI] [PubMed] [Google Scholar]
  • 37.Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999;255:735–739. doi: 10.1006/bbrc.1999.0248. [DOI] [PubMed] [Google Scholar]
  • 38.Sasaki T, Hohenester E, Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life. 2002;53:77–84. doi: 10.1080/15216540211466. [DOI] [PubMed] [Google Scholar]
  • 39.Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol. 2000;301:1179–1190. doi: 10.1006/jmbi.2000.3996. [DOI] [PubMed] [Google Scholar]
  • 40.Tsuda T, Wang H, Timpl R, Chu ML. Fibulin-2 expression marks transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and coronary vessels. Dev Dyn. 2001;222:89–100. doi: 10.1002/dvdy.1172. [DOI] [PubMed] [Google Scholar]
  • 41.Pan TC, Sasaki T, Zhang RZ, et al. Structure and expression of fibulin-2, a novel extracellular matrix protein with multiple EGF-like repeats and consensus motifs for calcium binding. J Cell Biol. 1993;123:1269–1277. doi: 10.1083/jcb.123.5.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gu YC, Talts JF, Gullberg D, Timpl R, Ekblom M. Glucocorticoids down-regulate the extracellular matrix proteins fibronectin, fibulin-1 and fibulin-2 in bone marrow stroma. Eur J Haematol. 2001;67:176–184. doi: 10.1034/j.1600-0609.2001.5790528.x. [DOI] [PubMed] [Google Scholar]
  • 43.Hamanaka T, Bill A, Ichinohasama R, Ishida T. Aspects of the development of Schlemm’s canal. Exp Eye Res. 1992;55:479–488. doi: 10.1016/0014-4835(92)90121-8. [DOI] [PubMed] [Google Scholar]
  • 44.Ethier CR. The inner wall of Schlemm’s canal. Exp Eye Res. 2002;74:161–172. doi: 10.1006/exer.2002.1144. [DOI] [PubMed] [Google Scholar]
  • 45.Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–225. doi: 10.1006/geno.1997.4778. [DOI] [PubMed] [Google Scholar]
  • 46.Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803–25810. [PubMed] [Google Scholar]
  • 47.Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351–360. [PubMed] [Google Scholar]
  • 48.Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999;38:618–626. doi: 10.1093/rheumatology/38.7.618. [DOI] [PubMed] [Google Scholar]
  • 49.Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int. 2001;20:192–196. doi: 10.1007/s002960100115. [DOI] [PubMed] [Google Scholar]
  • 50.Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol. 2001;30:297–304. doi: 10.1080/030097401753180381. [DOI] [PubMed] [Google Scholar]
  • 51.Bernardi D, Podswiadek M, Zaninotto M, Punzi L, Plebani M. YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin Chem. 2003;49:1685–1688. doi: 10.1373/49.10.1685. [DOI] [PubMed] [Google Scholar]
  • 52.Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599–605. doi: 10.1080/00365520310000537. [DOI] [PubMed] [Google Scholar]
  • 53.Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003;18:254–259. doi: 10.1007/s00384-002-0446-z. [DOI] [PubMed] [Google Scholar]
  • 54.Johansen JS, Moller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol. 1997;32:582–590. doi: 10.3109/00365529709025104. [DOI] [PubMed] [Google Scholar]
  • 55.Johansen JS, Christoffersen P, Moller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32:911–920. doi: 10.1016/s0168-8278(00)80095-1. [DOI] [PubMed] [Google Scholar]
  • 56.Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer. 1995;31:1437–1442. doi: 10.1016/0959-8049(95)00196-p. [DOI] [PubMed] [Google Scholar]
  • 57.Cintin C, Johansen JS, Christensen IJ, et al. Serum YKL-40 and colorectal cancer. Br J Cancer. 1999;79:1494–1499. doi: 10.1038/sj.bjc.6690238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Dehn H, Hogdall EV, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstetr Gynecol Scand. 2003;82:287–293. doi: 10.1034/j.1600-0412.2003.00010.x. [DOI] [PubMed] [Google Scholar]
  • 59.Johansen JS, Christensen IJ, Riisbro R, et al. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat. 2003;80:15–21. doi: 10.1023/A:1024431000710. [DOI] [PubMed] [Google Scholar]
  • 60.Shostak K, Labunskyy V, Dmitrenko V, et al. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett. 2003;198:203–210. doi: 10.1016/s0304-3835(03)00310-0. [DOI] [PubMed] [Google Scholar]
  • 61.Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687–694. doi: 10.1161/01.atv.19.3.687. [DOI] [PubMed] [Google Scholar]
  • 62.Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–2630. doi: 10.1002/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 63.Register TC, Carlson CS, Adams MR. Serum YKL-40 is associated with osteoarthritis and atherosclerosis in nonhuman primates. Clin Chem. 2001;47:2159–2161. [PubMed] [Google Scholar]
  • 64.De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285:926–931. doi: 10.1006/bbrc.2001.5253. [DOI] [PubMed] [Google Scholar]
  • 65.Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119–126. doi: 10.1042/BJ20020075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79–87. doi: 10.1016/s0014-4827(03)00069-7. [DOI] [PubMed] [Google Scholar]
  • 67.Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614–8622. [PubMed] [Google Scholar]
  • 68.Gonzalez P, Zigler JS, Jr, Epstein DL, Borras T. Identification and isolation of differentially expressed genes from very small tissue samples. Biotechniques. 1999;26:884–886. 888–892. doi: 10.2144/99265st01. [DOI] [PubMed] [Google Scholar]
  • 69.Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058–44067. doi: 10.1074/jbc.M306792200. [DOI] [PubMed] [Google Scholar]
  • 70.Volck B, Ostergaard K, Johansen JS, Garbarsch C, Price PA. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol. 1999;28:171–179. doi: 10.1080/03009749950154257. [DOI] [PubMed] [Google Scholar]
  • 71.Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci. 2003;44:473–485. doi: 10.1167/iovs.02-0444. [DOI] [PubMed] [Google Scholar]
  • 72.Miyahara T, Kikuchi T, Akimoto M, et al. Gene microarray analysis of experimental glaucomatous retina from cynomolgus monkey. Invest Ophthalmol Vis Sci. 2003;44:4347–4356. doi: 10.1167/iovs.02-1032. [DOI] [PubMed] [Google Scholar]
  • 73.Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A. Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. Matrix Biol. 2002;21:449–459. doi: 10.1016/s0945-053x(02)00028-8. [DOI] [PubMed] [Google Scholar]

RESOURCES